Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Regeneron history
Regeneron company history timeline
The company was founded by Alferd G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.“
One of our best hopes for fighting the coronavirus pandemic may have started with a signed napkin in 1988.
By 1989, Yancopoulos had bailed on Columbia to join Schleifer as Regeneron's chief scientific officer, setting up shop in Tarrytown, New York, about 20 miles north of Manhattan.
While many biotechs are secretive, Regeneron's researchers were encouraged to publish early and often, said Stahl, who joined in 1991.
Its early research helped the company gain some attention and raise $91 million in a 1991 initial public offering.
Approved by the FDA in February 2008.
By 2010, Regeneron had more than 1,000 employees and a market value north of $1 billion.
Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year®
Zaltrap (aflibercept injection) for metastatic colorectal cancer approved by the FDA in August 2012.
The drug brought in $1.4 billion in US sales in 2013 and has kept growing since then.
Regeneron was also cofounded by Eric Shooter, a Stanford University neuroscientist who served on the biotech's board until 2014.
Approved by the FDA in July 2015, It is reported to cost $4,500 to $8,000 per year.
Approved by the FDA in March 2017.
Approved by the FDA in September 2018.
On February 4, 2020, the United States Department of Health and Human Services, which already worked with Regeneron, announced that Regeneron would pursue monoclonal antibodies to fight COVID-19.
In October 2020 when United States President Donald Trump was infected with COVID-19 and taken to Walter Reed National Military Medical Center in Bethesda, Maryland, he was administered REGN-COV2.
In the filing, it specified that it currently had 50,000 doses and that it expected to reach a total of 300,000 doses "within the next few months." The FDA granted approval for emergency use authorization in November 2020.
Antibody drugs could be a "bridge to a vaccine" by being ready by the end of 2020.
Fortune: Change the World, 2020
2021: Regeneron among the 100 Fastest-Growing Companies
Great Place To Work: Fortune 100 Best Companies to Work For, 2021
Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022
Rate Regeneron's efforts to communicate its history to employees.
Regeneron jobs
Do you work at Regeneron?
Does Regeneron communicate its history to new hires?
Regeneron competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Gilead Sciences | 1987 | $28.8B | 11,800 | 739 |
| Johnson & Johnson | 1886 | $88.8B | 134,500 | 1,601 |
| Sanofi Genzyme | 1981 | $4.6B | 12,000 | - |
| Merck | 1891 | $64.2B | 74,000 | 1,772 |
| Amgen | 1980 | $33.4B | 22,000 | 645 |
| Baxter International | 1931 | $10.6B | 48,000 | 187 |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 287 |
| Zoetis | 1952 | $9.3B | 11,300 | 231 |
| Pfizer | 1849 | $63.6B | 78,500 | 511 |
| Genentech | 1976 | $166.9M | 13,638 | 526 |
Regeneron history FAQs
Zippia gives an in-depth look into the details of Regeneron, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Regeneron. The employee data is based on information from people who have self-reported their past or current employments at Regeneron. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Regeneron. The data presented on this page does not represent the view of Regeneron and its employees or that of Zippia.
Regeneron may also be known as or be related to Regeneron, Regeneron Pharmaceuticals, Regeneron Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc.